Non-Small Cell Lung Cancer (MET Alterations): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 67-year-old Chinese woman who presents at diagnosis with a moderate smoking history of ½ ppd for 15 years presented with episodes of cough, low-grade fever with weight loss in May 2014. Evaluation including a CT chest and PET/CT revealed a 4 cm mass with some bronchial obstruction and associated atelectasis of the lingular portion of the left upper lobe. Pathology showed a NSCLC with squamous differentiation

Originally posted on a forum in the ASCO Connection, participants now have the opportunity to claim CME, MOC, completion, or participation certificates for completing this activity.

Learning Objectives

  • Recognize the need for guideline-supported expanded molecular testing, including MET molecular alterations in the management of patients with advanced NSCLC
  • List the range of appropriate diagnostic modalities for the assessment of MET molecular alterations including MET exon 14 skipping and MET amplification
  • Identify the available treatment options including commercially available and experimental therapies that can be offered for patients identified with MET molecular aberrations

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Notes
  • This course expires on March 29, 2020. Participants must complete all necessary course components by this date to receive credit.